Insight for Sunday 12 August 2007
Pharmac's move to fund Herceptin under a nine-week treatment plan is seen by many as a compromise driven by cost.
It's also viewed as radical and experimental, with some claiming that the regime adopted here poses health risks to the women on it.
Karen Brown investigates.
Picture:Libby Burgess from the Breast Cancer Aotearoa Coalition